Clinical Trial Update: Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) [Phase 3]

View source ↗

Summary

A Phase 3 study assessing efficacy against oral persistent HPV infection, immunogenicity, and safety of Gardasil-9 (HPV vaccine, nonavalent) in men aged 20-45.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Gardasil 9 (Human papillomavirus vaccine, 9-valent)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Papillomavirus Infections | Phase 3 | Status: ACTIVE_NOT_RECRUITING